English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

ZAI Lab Announces Global Collaboration and License Agreement with UCB

Sep. 22, 2015

Zai Lab announced on September 22, 2015 that it has entered into a worldwide collaboration and license agreement with UCB, a global biopharmaceutical firm, to develop and commercialize a first-in-class monoclonal antibody for the potential treatment of autoimmune and other inflammatory diseases. The product is a clinical candidate ready for IND-enabling studies and expected to enter clinical Phase 1 in 2016.